OncologyCE

This activity is expired and is no longer available for CME credit.

EXPERT VIDEOCME

Hot Topics in Metastatic Breast Cancer Management: Clinical Advances with CDK4/6 Inhibitors

Author(s)/Faculty: Hope S. Rugo, MD; Joyce O'Shaughnessy, MD; Debu Tripathy, MD
Release Date: 1/20/2017Expiration Date: 12/21/2018
Credit Type: CMENumber of Credits: 0
Content Type: VideoProvider:
While the mortality rates for advanced or metastatic breast cancer (MBC) have steadily decreased, in part due to improved treatment options, the 5-year survival rate for MBC remains poor. Fortunately, emerging agents, such as targeted therapies, including the novel class of cyclin-dependent kinase (CDK) 4/6 inhibitors, may improve outcomes for patients with MBC. This CME activity will review the mechanisms of action of new and emerging targeted therapies, as well as evaluate the latest clinical evidence regarding the safety, efficacy, and recommended usage of available and emerging CDK4/6 inhibitors for the management of MBC.